These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29675797)

  • 21. Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin.
    Buysman EK; Fan T; Blauer-Peterson C; Miller-Wilson LA
    Endocrinol Diabetes Metab; 2018 Jul; 1(3):e00019. PubMed ID: 30815554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).
    Brož J; Janíčková Ždárská D; Štěpánová R; Kvapil M
    Diabetes Ther; 2019 Apr; 10(2):663-672. PubMed ID: 30788806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.
    Blonde L; Meneghini L; Peng XV; Boss A; Rhee K; Shaunik A; Kumar S; Balodi S; Brulle-Wohlhueter C; McCrimmon RJ
    Diabetes Ther; 2018 Jun; 9(3):1347-1358. PubMed ID: 29600507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).
    Maegawa H; Ishigaki Y; Langer J; Saotome-Nakamura A; Andersen M;
    J Diabetes Investig; 2021 Mar; 12(3):374-381. PubMed ID: 32643314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
    Lingvay I; Kirk AR; Lophaven S; Wolden ML; Shubrook JH
    Diabetes Ther; 2021 Mar; 12(3):879-896. PubMed ID: 33594582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating Glycemic Control in Patients with Type 2 Diabetes Suboptimally Controlled on Basal Insulin: UK ATTAIN Real-World Study.
    Jude EB; Nixon M; O'Leary C; Myland M; Gooch N; Shaunik A; Lew E
    Diabetes Ther; 2019 Oct; 10(5):1847-1858. PubMed ID: 31321748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study.
    Candido R; Nicolucci A; Larosa M; Rossi MC; Napoli R;
    Nutr Metab Cardiovasc Dis; 2023 Nov; 33(11):2294-2305. PubMed ID: 37679243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.
    Bellido D; Abellán P; Ruiz Palomar JM; Álvarez Sintes R; Nubiolae A; Bellido V; Romero G;
    Curr Ther Res Clin Exp; 2018; 89():37-42. PubMed ID: 30455779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
    Hoog M; Maldonado JM; Wangia-Dixon R; Halpern R; Buysman E; Gremel GW; Huang A; Konig M
    Diabetes Ther; 2024 Apr; 15(4):855-867. PubMed ID: 38427164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
    Chou HW; Cheng KP; Lin AC; Hung HC; Lin CH; Wang CC; Wu HT; Ou HY
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Retrospective Analysis of Therapeutic Inertia in Type 2 Diabetes Management Across a Diverse Population of Health Care Organizations in the USA.
    Rattelman CR; Ciemins EL; Stempniewicz N; Mocarski M; Ganguly R; Cuddeback JK
    Diabetes Ther; 2021 Feb; 12(2):581-594. PubMed ID: 33460018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone.
    Wright EE; Roberts GJ; Chuang JS; Nabutovsky Y; Virdi N; Miller E
    Diabetes Technol Ther; 2024 May; ():. PubMed ID: 38669474
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study.
    Candido R; Nicolucci A; Larosa M; Rossi MC; Napoli R;
    Nutr Metab Cardiovasc Dis; 2024 Aug; 34(8):1846-1853. PubMed ID: 38693036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people.
    Khunti K; Wolden ML; Thorsted BL; Andersen M; Davies MJ
    Diabetes Care; 2013 Nov; 36(11):3411-7. PubMed ID: 23877982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1149-1167. PubMed ID: 29675798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Changes in A1C Following Continuous Glucose Monitoring Acquisition in People with Sub-Optimally Treated Type 2 Diabetes Taking GLP-1 RA Therapy.
    Miller E; Chuang JS; Roberts GJ; Nabutovsky Y; Virdi N; Wright EE
    Diabetes Ther; 2024 Jul; ():. PubMed ID: 39008235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
    Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
    Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom.
    Brod M; Basse A; Markert M; Pfeiffer KM
    Diabetes Ther; 2019 Aug; 10(4):1323-1336. PubMed ID: 31127490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Glucagon-like Peptide-1 Receptor Agonists in Veterans Taking Basal/Bolus Insulin Regimens.
    Castek SL; Healey LC; Kania DS; Vernon VP; Dawson AJ
    Fed Pract; 2022 Nov; 39(Suppl 5):S18-S23. PubMed ID: 36923548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.